Clinical Trials Logo

Infections, Cytomegalovirus clinical trials

View clinical trials related to Infections, Cytomegalovirus.

Filter by:
  • None
  • Page 1

NCT ID: NCT06057194 Not yet recruiting - Clinical trials for Infections, Cytomegalovirus

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

LETERCOR
Start date: October 2023
Phase: Phase 2
Study type: Interventional

The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."

NCT ID: NCT01691820 Completed - Clinical trials for Infections, Cytomegalovirus

A Study in Adolescent Females to Explore Cytomegalovirus Infection

Start date: October 5, 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to estimate the incidence of Cytomegalovirus (CMV) secondary infections (re-infections/re-activations) and the incidence of CMV primary infections in adolescent females.

NCT ID: NCT01357915 Completed - Clinical trials for Infections, Cytomegalovirus

Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine

Start date: June 24, 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the persistence of the vaccine induced immune responses at Month 48 (Year 4) and Month 60 (Year 5) in healthy subjects who received 3 doses of GSK Biologicals' candidate CMV vaccine according to a 0-1-6 month schedule during the primary study 108890 (NCT00435396) (vaccine group). The immune response to CMV infection in naturally infected subjects who participated in the screening visit of the primary study 108890 (NCT00435396) and who were tested CMV-seropositive, will be used as a reference value (seropositive reference group). In addition, this study will continue to assess the occurrence of CMV infections as well as the continued development and validation of read-outs in the CMV project. The primary vaccination phase and Year 2 follow-up were posted as a separate protocol posting (NCT00435396).

NCT ID: NCT01251744 Completed - Clinical trials for Cytomegalovirus Infections

Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus

Start date: December 9, 2010
Phase: N/A
Study type: Interventional

This study is designed to evaluate maternal virological and immunological parameters to determine their ability to predict congenital cytomegalovirus (CMV) infection. When a pregnant woman is infected with CMV, her immune system (which protects her from infection) is activated and the virus can be found in the woman's bodily fluids (blood, saliva, urine, vaginal secretions). The aim of this study is to find out if there is a link between either the pregnant woman's immune response or the presence of the virus in these bodily fluids and the child/foetus being infected with the virus.

NCT ID: NCT00435396 Completed - Clinical trials for Infections, Cytomegalovirus

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Start date: February 22, 2007
Phase: Phase 1
Study type: Interventional

This will be the first time in humans (FTIH) study with the GSK Bio recombinant gB antigen to evaluate safety and immunogenicity of this CMV candidate vaccine with a proprietary GSK adjuvant system. The vaccine will be administered to young male healthy subjects at 0, 1 and 6 months. The trial will assess the safety and immunogenicity of the candidate CMV vaccine. An additional secondary objective of this trial is to identify and validate a test which will be able to differentiate between previous CMV infection and CMV vaccination. Subjects will be followed for a total of 2 years.